Clinical trials: Thyroid Tumor
Thyroid Cancer
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
The purpose of this study is to determine the safety and efficacy of oral lenvatinib in participants with medullary thyroid cancer (MTC) or radioiodine (131 I)-refractory/resistant differentiated thyroid cancer (DTC)…
- Trial name
- NCT00784303
- Testing
- Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort)
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor, Cholangiocarcinoma
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and…
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05253053
- Testing
- TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
- Where
- 9 sites in China
- Volunteers
- 84 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Poorly Differentiated Thyroid Carcinoma
PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
This is a prospective, multicenter, open label Phase II Clinical Trial. 30 advanced poorly differentiated thyroid carcinoma patients who were histopathologically confirmed inoperable were enrolled in this study.
- Trial name
- NCT03387943
- Testing
- PLD, Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Medullary Thyroid Carcinoma
Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma
This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor…
- Trial name
- NCT07713901
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 93,600,000 people
- Sponsor
- Novo Nordisk A/S
Melanoma, Glioma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors.
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT05538130
- Testing
- PF-07799544, PF-07799933
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 148 people
- Sponsor
- Pfizer
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC
Anaplastic Thyroid Cancer
Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
- Trial name
- FACT (NCT00507429)
- Testing
- CA4P, paclitaxel, carboplatin
- Where
- 41 sites in United States, Belarus and 10 more
- Volunteers
- 80 people
- Sponsor
- Mateon Therapeutics
Thyroid Neoplasms
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
This study was conducted in patients with differentiated thyroid cancer who had undergone near-total thyroidectomy. After surgery patients were randomized to one of two methods of performing thyroid remnant ablation (use of…
- Trial name
- NCT00196729
- Testing
- Thyrogen + Radioiodine (131I)
- Volunteers
- 63 people
- Sponsor
- Genzyme, a Sanofi Company
Thyroid Cancer
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in subjects with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local…
- Trial name
- NCT00121628
- Testing
- AMG 706
- Volunteers
- 184 people
- Sponsor
- Amgen
Anaplastic Thyroid Cancer
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
The Phase I/II study will be conducted as an open label, multiple center study of CS-7017, an experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid cancer.
- Trial name
- NCT00603941
- Testing
- CS-7017, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Daiichi Sankyo
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Breast Cancer, Hypercalcemia of Malignancy
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering…
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer
- Trial name
- NCT00896454
- Testing
- denosumab
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 33 people
- Sponsor
- Amgen
Medullary Thyroid Cancer
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
Study in healthy volunteers to assess effect of omeprazole and ranitidine on the pharmacokinetics of vandetanib
- Trial name
- Vandetanib (NCT01539655)
- Testing
- vandetanib, omeprazole, ranitidine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Thyroid Nodule (Benign)
HIFU Treatment of Benign Thyroid Nodules
This clinical trial is to evaluate the effectiveness and the safety of high intensity focused ultrasound (HIFU) in the treatment of benign thyroid nodules.
- Trial name
- NCT04233398
- Testing
- Device: Echopulse (HIFU ablation)
- Volunteers
- 240 people
- Sponsor
- Theraclion
Cancer, Non-small-cell Lung Cancer
Study of XL281 in Adults With Solid Tumors
The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer…
- Conditions
- Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer
- Trial name
- NCT00451880
- Testing
- XL281, famotidine
- Where
- 6 sites in United States
- Volunteers
- 180 people
- Sponsor
- Exelixis
Thyroid Nodule (Benign)
CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules
The objective of this clinical feasibility study is to evaluate initial clinical safety and device performance of the CellFX Percutaneous Electrode (PE) System for the treatment of symptomatic benign thyroid nodules.
- Trial name
- NCT06117085
- Testing
- CellFX® Percutaneous Electrode (PE) System
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Pulse Biosciences, Inc.